S&P 500   4,507.32 (+0.46%)
DOW   35,395.32 (+0.39%)
QQQ   373.97 (+0.35%)
AAPL   148.74 (+1.49%)
MSFT   308.64 (+0.44%)
FB   339.29 (+1.18%)
GOOGL   2,860.79 (+0.18%)
TSLA   869.86 (-0.03%)
AMZN   3,440.20 (-0.19%)
NVDA   221.44 (-0.35%)
BABA   172.93 (+3.66%)
NIO   39.78 (+0.43%)
CGC   13.35 (+1.14%)
GE   104.18 (+0.06%)
AMD   115.60 (-0.71%)
MU   66.83 (-0.64%)
T   25.38 (+0.20%)
F   15.51 (-0.32%)
ACB   6.95 (+0.43%)
DIS   170.48 (-0.39%)
PFE   41.91 (+1.43%)
BA   215.60 (-0.64%)
AMC   43.35 (+0.74%)
S&P 500   4,507.32 (+0.46%)
DOW   35,395.32 (+0.39%)
QQQ   373.97 (+0.35%)
AAPL   148.74 (+1.49%)
MSFT   308.64 (+0.44%)
FB   339.29 (+1.18%)
GOOGL   2,860.79 (+0.18%)
TSLA   869.86 (-0.03%)
AMZN   3,440.20 (-0.19%)
NVDA   221.44 (-0.35%)
BABA   172.93 (+3.66%)
NIO   39.78 (+0.43%)
CGC   13.35 (+1.14%)
GE   104.18 (+0.06%)
AMD   115.60 (-0.71%)
MU   66.83 (-0.64%)
T   25.38 (+0.20%)
F   15.51 (-0.32%)
ACB   6.95 (+0.43%)
DIS   170.48 (-0.39%)
PFE   41.91 (+1.43%)
BA   215.60 (-0.64%)
AMC   43.35 (+0.74%)
S&P 500   4,507.32 (+0.46%)
DOW   35,395.32 (+0.39%)
QQQ   373.97 (+0.35%)
AAPL   148.74 (+1.49%)
MSFT   308.64 (+0.44%)
FB   339.29 (+1.18%)
GOOGL   2,860.79 (+0.18%)
TSLA   869.86 (-0.03%)
AMZN   3,440.20 (-0.19%)
NVDA   221.44 (-0.35%)
BABA   172.93 (+3.66%)
NIO   39.78 (+0.43%)
CGC   13.35 (+1.14%)
GE   104.18 (+0.06%)
AMD   115.60 (-0.71%)
MU   66.83 (-0.64%)
T   25.38 (+0.20%)
F   15.51 (-0.32%)
ACB   6.95 (+0.43%)
DIS   170.48 (-0.39%)
PFE   41.91 (+1.43%)
BA   215.60 (-0.64%)
AMC   43.35 (+0.74%)
S&P 500   4,507.32 (+0.46%)
DOW   35,395.32 (+0.39%)
QQQ   373.97 (+0.35%)
AAPL   148.74 (+1.49%)
MSFT   308.64 (+0.44%)
FB   339.29 (+1.18%)
GOOGL   2,860.79 (+0.18%)
TSLA   869.86 (-0.03%)
AMZN   3,440.20 (-0.19%)
NVDA   221.44 (-0.35%)
BABA   172.93 (+3.66%)
NIO   39.78 (+0.43%)
CGC   13.35 (+1.14%)
GE   104.18 (+0.06%)
AMD   115.60 (-0.71%)
MU   66.83 (-0.64%)
T   25.38 (+0.20%)
F   15.51 (-0.32%)
ACB   6.95 (+0.43%)
DIS   170.48 (-0.39%)
PFE   41.91 (+1.43%)
BA   215.60 (-0.64%)
AMC   43.35 (+0.74%)
NASDAQ:ESPR

Esperion Therapeutics Price Target, Predictions & Analyst Ratings

$9.25
+0.39 (+4.40 %)
(As of 10/19/2021 10:27 AM ET)
Add
Compare
Today's Range
$8.37
$9.37
50-Day Range
$8.86
$14.52
52-Week Range
$8.37
$39.49
Volume12,083 shs
Average Volume748,698 shs
Market Capitalization$261.56 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14

Esperion Therapeutics (NASDAQ:ESPR) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Hold
Based on 10 Analyst Ratings

Analyst Price Target Consensus

$40.36

High PT$114.00
Average PT$40.36
Low PT$8.00
TypeCurrent
10/19/20 to 10/19/21
1 Month Ago
9/19/20 to 9/19/21
3 Months Ago
7/21/20 to 7/21/21
1 Year Ago
10/20/19 to 10/19/20
Consensus Rating
Hold
Hold
Hold
Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
8 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$40.36$45.09$49.27$80.50
Price Target Upside336.36% Upside98.30% Upside85.60% Upside74.52% Upside
Get Esperion Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Esperion Therapeutics (NASDAQ:ESPR) vs. Its Competitors

TypeEsperion TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.72
2.56
Consensus RatingHoldBuyBuy
Price Target Upside146.08% Upside7.82% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
576
71.38%
Underperform Votes
231
28.62%
Avg. Outperform Votes
178
67.42%
Avg. Underperform Votes
86
32.58%
Avg. Outperform Votes
830
69.46%
Avg. Underperform Votes
365
30.54%

Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/19/2021Cowen
Lower Price TargetPositive ➝ Outperform$60.00 ➝ $30.00+238.60%
10/18/2021Credit Suisse Group
DowngradeOutperform ➝ Neutral$28.00 ➝ $11.00+24.15%
10/14/2021Morgan Stanley
DowngradeEqual Weight ➝ Underweight$17.00 ➝ $11.00+5.77%
9/22/2021The Goldman Sachs Group
Lower Price TargetSell$16.00 ➝ $8.00-38.08%
9/14/2021JMP Securities
Reiterated RatingBuy$90.00+690.86%
8/3/2021Needham & Company LLC
Lower Price TargetStrong-Buy$134.00 ➝ $114.00+705.65%
5/11/2021Stifel Nicolaus
Reiterated RatingBuy ➝ Hold$37.00 ➝ $20.00-9.71%
5/5/2021BTIG Research
Lower Price Target$90.00 ➝ $71.00+269.60%
5/5/2021Northland Securities
Lower Price TargetMarket Perform$30.00 ➝ $24.00+34.45%
2/12/2021Jefferies Financial Group
DowngradeBuy ➝ Hold$40.00 ➝ $30.00-2.41%
1/15/2021Bank of America
DowngradeBuy ➝ Neutral$52.00 ➝ $35.00+30.84%
9/29/2020JPMorgan Chase & Co.
Initiated CoverageSell$35.00-5.71%
5/7/2020Citigroup
Boost Price TargetBuy$46.00 ➝ $56.00+37.93%
1/31/2020Chardan Capital
Gbola Amusa
Reiterated RatingHold$65.00+20.19%
(Data available from 10/19/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings Frequently Asked Questions

What is Esperion Therapeutics's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Esperion Therapeutics stock is Hold based on the current 2 sell ratings, 5 hold ratings, 2 buy ratings and 1 strong buy rating for ESPR. The average twelve-month price target for Esperion Therapeutics is $40.36 with a high price target of $114.00 and a low price target of $8.00. Learn more on ESPR's analyst rating history

Do Wall Street analysts like Esperion Therapeutics more than its competitors?

Analysts like Esperion Therapeutics stock less than the stock of other Medical companies. The consensus rating for Esperion Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how ESPR compares to other companies

Do MarketBeat users like Esperion Therapeutics more than its competitors?

MarketBeat users like Esperion Therapeutics stock more than the stock of other Medical companies. 71.38% of MarketBeat users gave Esperion Therapeutics an outperform vote while medical companies recieve an average of 67.42% outperform votes by MarketBeat users.

Is Esperion Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Esperion Therapeutics's stock had 2 downgrades by analysts.

Does Esperion Therapeutics's stock price have much upside?

According to analysts, Esperion Therapeutics's stock has a predicted upside of 144.04% based on their 12-month price targets.

What analysts cover Esperion Therapeutics?

Esperion Therapeutics has been rated by Cowen, Credit Suisse Group, JMP Securities, Morgan Stanley, Needham & Company LLC, and The Goldman Sachs Group in the past 90 days.

This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.